ATI
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Globally, ATI Inc. stands as a premier manufacturer and supplier of specialized materials and complex components. The enterprise's operations are strategically divided into two primary divisions: High...
Latest News
13 hours ago · zacks.com
Buy These 5 Top-Ranked High-Efficiency Stocks With Strong Profit PotentialFive stocks, including Avnet, ATI and Suncor Energy, stand out for their strong efficiency metrics, above-industry-average ratios and earnings surprises.
21 hours ago · globenewswire.com
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options - - Unique Mechanism Targets Key Pathways Implicated in LP Pathology, T-cell Receptor Signaling Upstream and Effector Cytokine Signaling Downstream - WAYNE, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus (LP); the first cohort to be enrolled will be patients with oral erosive lichen planus (OLP).
21 hours ago · globenewswire.com
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)- The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 - - Aclaris Remains Focused on Prioritizing the Development of its Oral Kinase (ITK) Inhibitors and Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 - WAYNE, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced top line results from the Phase 2 ADMIRATION trial that evaluated the efficacy and safety of bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, in patients with moderate-to-severe atopic dermatitis.
3 days ago · marketbeat.com
ATI Targets $7 Billion by 2029, Sees More Runway in Aerospace and DefenseATI NYSE: ATI expects growth in aerospace, defense and specialty energy to extend beyond 2029, with potential upside from faster aircraft production, increased defense spending and market-share gains, Chairman, President and CEO Kim Fields said during a company event.
4 days ago · gurufocus.com
ATI Unveils Acceleration Strategy, Targets Double-Digit Growth and Expanded MarginsATI Unveils Acceleration Strategy, Targets Double-Digit Growth and Expanded MarginsPR NewswireCHARLOTTE, N.C., Nov. 12, 2026Announces investments in high-demand
7 days ago · zacks.com
3 Reasons Growth Investors Will Love ATI (ATI)ATI (ATI) could produce exceptional returns because of its solid growth attributes.
8 days ago · zacks.com
ATI's Shares Rally 53% YTD: Should You Buy the Stock Now?ATI's shares have surged 53.2% YTD, fueled by aerospace and defense demand, capacity expansion and higher guidance.
12 days ago · zacks.com
Can ATI Leverage Strong Cash Generation to Strengthen Returns?ATI's strong cash flow growth, higher EBITDA guidance and disciplined buybacks highlight its efforts to reduce debt and strengthen shareholder returns.
13 days ago · zacks.com
Best Growth Stocks to Buy for November 4thMDB, ATI, and OSCR it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 4, 2026.
15 days ago · zacks.com
ATI Q3 Earnings Beat Estimates on Aerospace Demand, Outlook RaisedATI's Q3 earnings jump 71.8% on strong aerospace demand and pricing, prompting higher 2026 guidance as commercial jet engine sales fueled growth.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ATI